The NCCN 2022 Annual Conference took place from March 30 to April 1 as a virtual event. Designed to meet the educational needs of the interprofessional oncology care team, the conference offered more than 30 educational sessions featuring the latest advances and experts in oncology care. On this episode of the podcast, we’ll hear from three speakers who discussed recent advances in cancer care in their respective fields.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this week’s episode, we are discussing two recent FDA approvals—one for prostate cancer, and the other for endometrial cancer. The radioconjugate lutetium Lu-177 vipivotide tetraxetan was approved for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Pembrolizumab was approved as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair–deficient as determined by an FDA-approved test; eligible patients have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Radioligand for Metastatic Castration-Resistant Prostate Cancer

FDA Approves Pembrolizumab for Advanced Endometrial Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this week’s episode, we’ll discuss a recent FDA approval in germline BRCA-mutated, HER2-negative, high-risk early breast cancer. Then, we’ll hear about the publication of final overall survival results from the MONALEESA-2 trial, which evaluated the efficacy of the addition of ribociclib to letrozole in the first-line treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer

Final Overall Survival Analysis of MONALEESA-2: Addition of Ribociclib to Letrozole in Postmenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this week’s episode, we’ll discuss a recent U.S. Food and Drug Administration (FDA) approval in the early-stage non–small cell lung cancer setting. Then, we’ll hear about a study presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium that investigated methods for the de-escalation of radiation therapy for oropharyngeal cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLC

Midtreatment Imaging De-escalates Therapy for Half of Patients With Oropharyngeal Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

The 2022 Multidisciplinary Head and Neck Cancers Symposium took place from February 24 to 26 in Phoenix, Arizona. The meeting provided the most up-to-date information on multidisciplinary therapies, clinical research, treatment strategies, supportive care, and scientific breakthroughs in head and neck cancer. On this episode of the podcast, we’ll hear from three authors who presented their research at the meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we’re highlighting three presentations from the ASCO Genitourinary Cancers Symposium, held recently in San Francisco.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

The 2022 ASCO Genitourinary Cancers Symposium kicked off this week. On this episode, we’ll hear about two studies presented at the meeting: one, focused on a genetic risk score that may aid in identifying men with high vs low lifetime risks of developing metastatic prostate cancer or dying from prostate cancer; and the second, about a trial that tested the efficacy of combination immunotherapy and tyrosine kinase inhibitor therapy for renal cell carcinoma.

Coverage of stories discussed this week on ascopost.com:

Comprehensive Genetic Risk Score May Predict Risk of Developing Metastatic Prostate Cancer or Death From Prostate Cancer Across Diverse Populations

To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we’ll review a report on the KRYSTAL-1 trial of adagrasib therapy in various gastrointestinal cancers, and highlight key points from the newly released AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care.

Coverage of stories discussed this week on ascopost.com:

KRYSTAL-1: Adagrasib Controls Disease in Gastrointestinal Malignancies Beyond Colorectal Cancer

AACR Releases Report on the Impact of COVID-19 on Cancer Research and Patient Care

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we're reviewing a statement issued by the White House earlier this week on the Cancer Moonshot initiative.

Coverage of stories discussed this week on ascopost.com:

President Biden Reignites Cancer Moonshot

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’ll be talking about an FDA approval for uveal melanoma, as well as the efficacy of PD-1 inhibition in patients with resectable liver cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma

Neoadjuvant Cemiplimab-rwlc for Patients With Resectable Hepatocellular Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.